CZ143998A3 - Substituované diaminokarboxylové kyseliny, způsob jejich přípravy, léčivo, které je obsahuje, a jejich použití - Google Patents

Substituované diaminokarboxylové kyseliny, způsob jejich přípravy, léčivo, které je obsahuje, a jejich použití Download PDF

Info

Publication number
CZ143998A3
CZ143998A3 CZ981439A CZ143998A CZ143998A3 CZ 143998 A3 CZ143998 A3 CZ 143998A3 CZ 981439 A CZ981439 A CZ 981439A CZ 143998 A CZ143998 A CZ 143998A CZ 143998 A3 CZ143998 A3 CZ 143998A3
Authority
CZ
Czechia
Prior art keywords
group
formula
substituted
alkyl
phenyl
Prior art date
Application number
CZ981439A
Other languages
Czech (cs)
English (en)
Inventor
Werner Dr. Thorwart
Wilfried Dr. Schwab
Manfred Dr. Schudok
Burkhard Dr. Haase
Bernhard Dr. Neises
Günter Dr. Billen
Original Assignee
Hoechst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19719585A external-priority patent/DE19719585A1/de
Priority claimed from DE19719428A external-priority patent/DE19719428A1/de
Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft
Publication of CZ143998A3 publication Critical patent/CZ143998A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CZ981439A 1997-05-09 1998-05-07 Substituované diaminokarboxylové kyseliny, způsob jejich přípravy, léčivo, které je obsahuje, a jejich použití CZ143998A3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19719585A DE19719585A1 (de) 1997-05-09 1997-05-09 Substituierte Diaminocarbonsäuren
DE19719428A DE19719428A1 (de) 1997-05-12 1997-05-12 Substituierte Diaminocarbonsäuren

Publications (1)

Publication Number Publication Date
CZ143998A3 true CZ143998A3 (cs) 1998-11-11

Family

ID=26036417

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ981439A CZ143998A3 (cs) 1997-05-09 1998-05-07 Substituované diaminokarboxylové kyseliny, způsob jejich přípravy, léčivo, které je obsahuje, a jejich použití

Country Status (18)

Country Link
US (2) US6159995A (enExample)
EP (1) EP0877019B1 (enExample)
JP (1) JP4177484B2 (enExample)
KR (1) KR19980086893A (enExample)
AR (1) AR012675A1 (enExample)
AT (1) ATE210639T1 (enExample)
AU (1) AU736700B2 (enExample)
BR (1) BR9801604A (enExample)
CA (1) CA2237052A1 (enExample)
CZ (1) CZ143998A3 (enExample)
DE (1) DE59802394D1 (enExample)
DK (1) DK0877019T3 (enExample)
ES (1) ES2165640T3 (enExample)
HU (1) HUP9801045A3 (enExample)
ID (1) ID20809A (enExample)
PL (1) PL326218A1 (enExample)
PT (1) PT877019E (enExample)
TR (1) TR199800818A3 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19719621A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
PL342009A1 (en) 1998-02-04 2001-05-07 Novartis Ag Sulphonylamine derivatives capable to inhibit extracellular substance degrading metaloproteinases
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
RU2217418C2 (ru) * 1998-04-03 2003-11-27 Санкио Компани, Лимитед Сульфонамидное производное, лекарственное средство, способы лечения
EP1097159B1 (de) 1998-07-16 2002-11-06 Aventis Pharma Deutschland GmbH Phosphin- und phosphonsäurederivate als arzneimittel
KR20010102486A (ko) * 1999-03-03 2001-11-15 데이비드 엠 모이어 알케닐- 및 알키닐-함유 메탈로프로테아제 저해제
SK12462001A3 (sk) 1999-03-03 2002-04-04 The Procter & Gamble Company Inhibítory metaloproteáz
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0103303D0 (en) * 2001-02-09 2001-03-28 Novartis Ag Organic compounds
US6506786B2 (en) * 2001-02-13 2003-01-14 Pharmacor Inc. HIV protease inhibitors based on amino acid derivatives
JP4294321B2 (ja) * 2001-03-14 2009-07-08 ノバルティス アクチエンゲゼルシャフト Ｍｍｐ阻害剤としての使用のためのアザシクロアルキル置換酢酸誘導体
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
US20060287316A1 (en) * 2005-04-27 2006-12-21 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
WO2007062526A1 (en) * 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
ES2628730T3 (es) 2006-09-21 2017-08-03 Taimed Biologics, Inc. Inhibidores de proteasa
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
US8093265B2 (en) 2007-03-09 2012-01-10 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
HUE057569T2 (hu) 2014-12-17 2022-05-28 Pimco 2664 Ltd N-(4-hidroxi-4-metil-ciklohexil)-4-fenil-benzolszulfonamid és N-(4-hidroxi-4-metil-ciklohexil)-4-(2-piridil)-benzolszulfonamid vegyületek és terápiás alkalmazásuk
US11289654B2 (en) 2016-12-22 2022-03-29 Guangzhou Chinaray Optoelectronic Materials Ltd. Polymers containing furanyl crosslinkable groups and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2764262B2 (ja) * 1987-08-28 1998-06-11 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とする医薬組成物
TW201303B (enExample) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
AU690703B2 (en) * 1994-06-22 1998-04-30 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) * 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
SK282833B6 (sk) * 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
JPH10265452A (ja) 1996-05-24 1998-10-06 Ono Pharmaceut Co Ltd フェニルスルホンアミド誘導体

Also Published As

Publication number Publication date
TR199800818A2 (xx) 1998-11-23
ID20809A (id) 1999-03-11
JP4177484B2 (ja) 2008-11-05
DK0877019T3 (da) 2002-04-08
HUP9801045A3 (en) 2000-09-28
BR9801604A (pt) 1999-06-08
AU736700B2 (en) 2001-08-02
US6355673B1 (en) 2002-03-12
TR199800818A3 (tr) 1998-11-23
HUP9801045A2 (hu) 1999-06-28
ES2165640T3 (es) 2002-03-16
KR19980086893A (ko) 1998-12-05
US6159995A (en) 2000-12-12
HU9801045D0 (en) 1998-07-28
PL326218A1 (en) 1998-11-23
JPH11228529A (ja) 1999-08-24
ATE210639T1 (de) 2001-12-15
EP0877019A1 (de) 1998-11-11
PT877019E (pt) 2002-05-31
AU6482498A (en) 1998-11-12
AR012675A1 (es) 2000-11-08
EP0877019B1 (de) 2001-12-12
DE59802394D1 (de) 2002-01-24
CA2237052A1 (en) 1998-11-09

Similar Documents

Publication Publication Date Title
AU736700B2 (en) Substituted diaminocarboxylic acids
CZ143898A3 (cs) Sulfonylaminokarboxylové kyseliny, způsob jejich přípravy, léčivo, které je obsahuje, a jejich použití
JP2000502664A (ja) アルファ―ｖ―インテグリン阻害剤としてのチロシン誘導体
KR20230035602A (ko) CCR8 억제제로 Tregs를 표적화하는 방법 및 조성물
CA2321538A1 (en) Disubstituted pyrazolines and triazolines as factor xa inhibitors
US5962640A (en) Methods for preparing novel dipeptide compounds or pharmacuetically acceptable salts thereof
SK17252002A3 (sk) Deriváty acylfenylmočoviny, spôsoby ich výroby a použitie ako liečivo
CA2321348A1 (en) Aromatic derivatives with hiv integrase inhibitory properties
CA2250464A1 (en) Meta-substituted phenylene derivatives and their use as alphavbeta3 integrin antagonists or inhibitors
GB2441396A (en) Indoline sulfonamide compounds
ES2294103T3 (es) Inhibidores de vih proteasa con base en derivados de aminoacidos.
IE60332B1 (en) N-(2'aminophenyl)-benzamide-derivatives, process for their preparation and their use in the control of neoplastic diseases
CN1658877B (zh) 碱性非肽缓激肽拮抗剂及其药物组合物
RU2632206C2 (ru) Новые алкилирующие средства
US6706753B2 (en) Integrin receptor inhibitors
ES2235383T3 (es) Beta-alaninas sustituidas.
KR20010080385A (ko) Ｎ-아릴설포닐 아미노산 오메가 아미드
KR101771760B1 (ko) 우레탄, 요소, 아미딘 및 관련된 Ｘａ 인자의 억제제
EP1480941B1 (en) Urea derivatives as hiv aspartyl protease inhibitors
US5310916A (en) Trifunctional agents useful as irreversible inhibitors of A1-adenosine receptors
RU2196768C2 (ru) Замещенные диаминокарбоновые кислоты
EP1270569A1 (en) Substituted tryptophan derivatives
CA2374362C (en) Urea derivatives as hiv aspartyl protease inhibitors
CN105153163B (zh) 2,9‑二取代嘌呤‑6‑氨基异羟肟酸类组蛋白去乙酰化酶抑制剂及制备方法和应用
WO2016107541A1 (zh) 吡咯酰胺类化合物及其制备方法与用途

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic